GlassScriptPhysician profile
Pamela M Mize
NPI 1245726512
$357.36
in general payments reported to CMS, 2019-2025
14 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.78 · 2024: $212 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $65.01 | 2023-2025 | |
| Shockwave Medical, INC | $52.27 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $37.60 | 2024-2025 | |
| Abbvie INC. | $27.01 | 2025 | |
| Scpharmaceuticals INC. | $23.31 | 2024 | |
| Boston Scientific Corporation | $22.70 | 2024 | Watchman Access System |
| Philips North America LLC | $19.30 | 2024 | (6536) Phoenix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.77 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $16.58 | 2024 | Xarelto |
| Sumitomo Pharma America, INC. | $16.20 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.12 | 2024 | Xifaxan |
| Antares Pharma, INC. | $15.57 | 2025 | Xyosted |
| Lexicon Pharmaceuticals, INC. | $14.53 | 2024 | |
| Phathom Pharmaceuticals, INC. | $12.39 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Mize listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.